Search clinical trials for: Endothelin A Receptor Antagonists

Total 10180 results

Mayo Clinic
National Institutes of Health (NIH)

Completed

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

Endothelial Dysfunction

United States
AbbVie (prior sponsor, Abbott)

Completed

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Diabetic Nephropathy | Chronic Kidney Disease

United States
The George Institute

Not yet recruiting

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)

Chronic Kidney Diseases
Janssen Pharmaceutical K.K.

Completed

A Study of Macitentan, in Healthy Japanese Male Participants

Healthy

Japan
AbbVie

Terminated

Study Of Diabetic Nephropathy With Atrasentan (SONAR)

Diabetic Nephropathy
Actelion

Withdrawn

Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension (LONGACT)

Pulmonary Arterial Hypertension
AbbVie (prior sponsor, Abbott)

Completed

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (RADAR)

Diabetic Nephropathy | Chronic Kidney Disease

United States, Canada, Puerto Rico, Taiwan
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Actelion

Completed

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (TRITON)

Pulmonary Arterial Hypertension

United States, Spain, Denmark, Canada, Germany, United Kingdom, Belgium, Austria, Netherlands, Australia, France, Ireland, Sweden, Italy, Switzerland
Actelion

Terminated

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) (OPTIMA)

Pulmonary Arterial Hypertension

France
Janssen Research & Development, LLC

Completed

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Healthy

United States
Actelion

Terminated

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

Glioblastoma

United States
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Canada, Australia, Germany, France, India, Japan, Argentina, Italy, Brazil, Colombia, Poland, Portugal
Chinook Therapeutics, Inc.

Recruiting

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST)

Immunoglobulin A Nephropathy | IgA Nephropathy

Spain, United States, Australia, Korea, Republic of, Brazil, Malaysia
Actelion

Terminated

Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma

Glioblastoma

United States
Actelion

Completed

Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults

Healthy Subjects

Czech Republic
Actelion

Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (UNISUS)

Pulmonary Arterial Hypertension

Belgium, United States, Italy, Canada, Taiwan, Greece, China, Korea, Republic of, Germany, Israel, Austria, Russian Federation, Australia, Thailand, United Kingdom, Brazil, Malaysia, Spain, Ukraine, Bulgaria, Colombia, Mexico, Turkey, Vietna... and more
AbbVie (prior sponsor, Abbott)

Completed

Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan

Diabetic Nephropathy | Chronic Kidney Disease

Japan
University of Edinburgh
British Heart Foundation

Completed

Endothelin Receptor Antagonism in Proteinuric Nephropathy

Proteinuria | Chronic Kidney Disease

United Kingdom
Radboud University Medical Center
UMC Utrecht; Catharina Ziekenhuis Eindhoven; Maasstad Hospital

Not yet recruiting

Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm (EDIT-CAS)

Coronary Spasm

Netherlands
Xuzhou Medical University

Unknown

the Effect of Tracleer on Tourniquet-associated Hypertension

Hypertension | Tourniquets | Bosentan

China
Actelion

Completed

A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

Healthy Subjects

Germany
Actelion

Completed

Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects

Healthy Subjects

Germany
MelCure SA
Universitaire Ziekenhuizen KU Leuven; University of Bern; California Institute...

Terminated

Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma

Melanoma
Actelion

Recruiting

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PLATYPUS)

Hypertension, Pulmonary

Korea, Republic of, Taiwan, Poland, Bulgaria, Ukraine, Belgium, South Africa, Belarus, Russian Federation
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital; Abbott

Completed

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Pfizer

Terminated

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Resistant Hypertension

United States
Janssen Research & Development, LLC

Completed

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

Healthy

Belgium
Actelion
Canadian Heart Research Centre

Completed

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (PAH QuERI Ext)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Actelion

Active, not recruiting

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (A DUE)

Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

United States, Japan, Taiwan, Turkey, Canada, China, Germany, Spain, Italy, Malaysia, Hungary, Russian Federation, Brazil, Australia, Bulgaria, Czechia, Mexico, Poland, South Africa
Actelion

Completed

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

Healthy

United States
Amsterdam UMC, location VUmc

Unknown

Goal Oriented Strategy to Preserve Ejection Fraction Trial (GOSPEL)

Pulmonary Arterial Hypertension

Netherlands
Actelion

Completed

Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects

Healthy

Germany
University Hospital, Rouen

Completed

Role of Endothelin-1 in Flow-mediated Dilatation (Endothelin)

Healthy Conditions

France
AbbVie (prior sponsor, Abbott)

Completed

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Diabetic Nephropathy | Chronic Kidney Disease

United States, Puerto Rico
Medical University of Vienna

Completed

Endothelin-Receptor Blockade in Coronary Heart Disease

Vascular Resistance | Coronary Vessels | Endothelins

Austria
Actelion

Completed

A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants

Healthy

Belgium
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University of Southern Denmark
The University of Texas at Arlington

Active, not recruiting

Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes

Type2 Diabetes

Denmark
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Prostate Cancer | Metastatic Cancer

United States
Pfizer

Terminated

A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Hypertension, Pulmonary

Japan
Universitair Ziekenhuis Brussel

Completed

Transcranial Doppler in Multiple Sclerosis (TRADOMS)

Multiple Sclerosis

Belgium
Hospital Universitario Getafe

Completed

Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan

Thromboangiitis Obliterans

Spain
Pfizer

Terminated

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (STRIDE-3)

Pulmonary Arterial Hypertension

United States, Netherlands, Canada, Belgium, France, Germany, Italy, Spain, United Kingdom, Australia, Poland, Austria, Brazil, Israel, Argentina, Mexico
ICOS-Texas Biotechnology
ICOS Corporation; Texas Biotechnology Corporation

Unknown

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States, Canada
Pfizer

Terminated

Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Hypertension, Pulmonary

Japan
University of Edinburgh
Encysive Pharmaceuticals

Completed

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

Pulmonary Arterial Hypertension | Vasodilation | Vasoconstriction

United Kingdom
Assistance Publique - Hôpitaux de Paris
Actelion

Completed

Effect of Bosentan in Scleroderma Renal Crisis (ScS-REINBO)

Scleroderma Renal Crisis

France
Actelion

Completed

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma

Scleroderma, Systemic | Pulmonary Fibrosis

United States, Israel, France, United Kingdom, Netherlands, Switzerland, Germany, Italy, Sweden
Georgetown University
Actelion

Terminated

Placebo Controlled Trial of Bosentan in Scleroderma Patients

Systemic Scleroderma | Pulmonary Hypertension

United States

Search clinical trials for: Endothelin A Receptor Antagonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations